Highlighted Webinar
Discover our most watched webinar and learn groundbreaking insights from Dr. Marcela Maus, Dr. Marco Ruella, Prof. Mark Lowdell and others!
Understanding the mechanism of action of a novel dual CAR approach with improved efficacy and safety using Cell Avidity
Watch this webinar to learn how cell avidity was used to understand the mechanism of action of the trans-singalling stratergy of dual CAR-CIK cells
On-demand Webinars
Uncover a range of on-demand webinars delivered by our application scientists or invited speakers on a wide range of topics.
Improving CAR-T Immunotherapy for Lymphoma by fine-tuning avidity
Commercial CAR-T therapies still suffer from severe limitations, as majority of patients fail to achieve complete response and ultimately relapse.
Cell avidity of CAR-NK cells revealed as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control
Dr. Peter Chockley demonstrates how cell avidity measurements directly linked to synapse quality and in vivo tumor clearance using CAR-NK avidity-tuned cells
How cell avidity between tumor-effector cell pairs drives the efficacy of cellular immunotherapy
Measuring cell avidity provides a more complete and physiologically relevant picture of the cell-cell interaction.
TCR- and BsAb-induced interaction drives avidity-based cellular immunotherapy efficacy
Cell avidity measures the effectiveness of the events during immunological synapse formation.
Unveiling a one-to-one relationship of TCR-dependent T cell function and cellular avidity at single-cell level using acoustic force
The cell avidity experiments provided for the team of Dr. Nathalie Rufer shows a better in vivo correlation.
Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma
Prof. de Larrea demonstrated reduced relapse through dual-targeting CAR T approaches.
Exploring the network of cellular interactions of Natural Killer cells in the tumor microenvironment with cell avidity
Prof. Mark Lowdell discussed how primed NK cells become effective in resistant tumor cell killing through stronger binding.
Enhanced avidity through combining a BCMA CAR and a CD38 chimeric co-stimulatory receptor leads to enhanced T cell sensitivity and persistence
Dr. Maria Themeli showed how to overcome low antigen density and improve CAR-T cell persistence with multi-targeting and co-stimulation.
Cell avidity as a crucial biomarker for CAR T response
Dr. Rebecca Larson’s work revealed important evasion mechanism from CAR T cell response in solid tumors.
Cell Avidity Measurements to Understand and Enhance CAR-T/Tumor Interactions in Acute Myeloid Leukemia
Dr. Marcela Maus used avidity measurements to understand and enhance productive CAR-T cell interactions.
© 2024 LUMICKS.
Specifications and equipment are subject to change without any notice or obligation on the part of the manufacturer.
Privacy Policy | Code of Conduct
Download our webinar recording:
Download our Cell Therapy (CAR-T, TCR, NK) applications deck